Table 2 Afatinib starting dose, dose adjustment and optimal dose and treatment of baseline brain metastases
| Treatment Pattern and Outcome |
Total number of patients (n = 85) |
|---|---|
| Afatinib starting dose, No. (%) | |
| 40 mg once daily | 45 (52.9) |
| 30 mg once daily | 30 (35.3) |
| 25 mg once daily | 3 (3.5) |
| 20 mg once daily | 7 (8.2) |
| Afatinib dose adjustment, No. (%) | |
| Starting dose maintained | 49 (57.6) |
| Dose increased | 10 (11.8) |
| Dose reduced | 26 (30.6) |
| Afatinib optimum dose, No. (%) | |
| 50 mg once daily | 4 (4.7) |
| 40 mg once daily | 30 (35.3) |
| 30 mg once daily | 30 (35.3) |
| 25 mg once daily | 12 (14.1) |
| 20 mg once daily | 9 (10.6) |
| Brain metastasis treatment, No. (%) | |
| No brain metastases | 60 (70.6) |
| Afatinib alone | 4 (4.7) |
| Afatinib with surgery or radiotherapy | 21 (24.7) |